Profile data is unavailable for this security.
About the company
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
- Revenue in USD (TTM)260.50k
- Net income in USD-19.03m
- Incorporated2010
- Employees8.00
- LocationInhibikase Therapeutics Inc3350 Riverwood Parkway Se, Suite 1900ATLANTA 30339United StatesUSA
- Phone+1 (678) 392-3419
- Fax+1 (302) 655-5049
- Websitehttps://www.inhibikase.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galera Therapeutics Inc | 0.00 | -45.75m | 10.62m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Monopar Therapeutics Inc | 0.00 | -7.61m | 10.80m | 10.00 | -- | 1.44 | -- | -- | -0.5289 | -0.5289 | 0.00 | 0.4277 | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| BioCardia Inc | 477.00k | -11.57m | 10.82m | 16.00 | -- | -- | -- | 22.67 | -0.5525 | -0.5525 | 0.0225 | -0.0677 | 0.0747 | -- | 3.61 | 29,812.50 | -181.08 | -107.34 | -414.21 | -154.17 | -- | -- | -2,425.79 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Eterna Therapeutics Inc | 68.00k | -21.68m | 10.98m | 8.00 | -- | 4.92 | -- | 161.51 | -4.08 | -4.08 | 0.0128 | 0.4128 | 0.0019 | -- | 0.0988 | 8,500.00 | -60.69 | -169.05 | -75.78 | -223.00 | -173.53 | -- | -31,864.71 | -682.61 | -- | -33.19 | 0.7813 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Guardion Health Sciences Inc | 12.25m | 158.03k | 11.07m | 9.00 | 69.37 | 1.35 | 62.38 | 0.9037 | 0.1243 | 0.1243 | 9.66 | 6.39 | 0.729 | 2.36 | 5.83 | 1,360,951.00 | 0.9405 | -77.90 | 1.12 | -86.55 | 44.04 | 42.45 | 1.29 | -176.93 | 6.98 | -- | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| ABVC Biopharma Inc | 152.43k | -10.52m | 11.19m | 16.00 | -- | 1.00 | -- | 73.44 | -2.52 | -2.52 | 0.0352 | 1.06 | 0.0127 | -- | 0.3514 | 9,526.88 | -90.65 | -103.38 | -171.60 | -231.54 | -98.15 | 76.25 | -7,157.57 | -2,019.89 | -- | -3.28 | 0.153 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| ELEVAI Labs Inc | 1.71m | -4.30m | 11.27m | 18.00 | -- | 2.94 | -- | 6.58 | -0.2482 | -0.2482 | 0.0988 | 0.2208 | -- | -- | -- | 95,143.89 | -- | -- | -- | -- | 66.25 | -- | -251.17 | -- | 3.41 | -41.16 | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 260.50k | -19.03m | 11.40m | 8.00 | -- | 0.9918 | -- | 43.76 | -3.62 | -3.62 | 0.0489 | 1.77 | 0.0132 | -- | 13.06 | 32,562.50 | -96.49 | -66.49 | -117.79 | -85.55 | -- | -- | -7,304.76 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -29.77m | 11.63m | 18.00 | -- | 0.4297 | -- | -- | -15.06 | -15.06 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -62.25 | -46.84 | -70.87 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -10.01m | 11.73m | 9.00 | -- | -- | -- | -- | -2.04 | -2.04 | 0.00 | -0.0346 | 0.00 | -- | -- | 0.00 | -110.06 | -149.95 | -1,281.64 | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Chromocell Therapeutics Corp | 0.00 | -7.38m | 11.81m | 4.00 | -- | -- | -- | -- | -1.28 | -1.28 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -9,746.19 | -- | -- | -- | -- | -- | -- | -- | -- | -13.23 | -- | -- | -- | -- | -200.20 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -20.42m | 11.85m | 5.00 | -- | -- | -- | -- | -4,118.49 | -4,118.49 | 0.00 | -9.35 | 0.00 | -- | -- | 0.00 | -90.14 | -- | -2,340.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02 | -- | -- | -- |
| Pioneer Green Farms Inc | 9.29k | -403.37k | 11.94m | 6.00 | -- | -- | -- | 1,285.15 | -0.0172 | -0.0172 | 0.0004 | -0.026 | 0.0154 | 0.3035 | -- | 1,548.33 | -66.94 | -- | -- | -- | 41.44 | -- | -4,341.98 | -- | 0.0106 | -30.89 | -- | -- | -- | -- | 35.41 | -- | -- | -- |
| 22nd Century Group Inc | 32.20m | -64.68m | 12.00m | 64.00 | -- | -- | -- | 0.3728 | -49.97 | -116.47 | 29.49 | -3.09 | 0.4531 | 5.70 | 8.81 | 503,187.50 | -76.94 | -46.78 | -105.06 | -54.18 | -27.00 | -2.11 | -169.81 | -107.95 | 0.4766 | -4.62 | 2.39 | -- | -20.49 | 4.03 | -76.94 | -- | 53.60 | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 12.19m | -- | -- | -- | 8.04 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Inhibikase Therapeutics Inc's reporting currency: US Dollar USD
7.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FiveT Capital AGas of 09 Feb 2023 | 223.50k | 3.61% |
| William Blair Investment Management LLCas of 31 Mar 2024 | 76.60k | 1.24% |
| Geode Capital Management LLCas of 31 Dec 2023 | 28.69k | 0.46% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 24.42k | 0.40% |
| G1 Execution Services LLCas of 31 Mar 2024 | 22.62k | 0.37% |
| Redmond Asset Management LLCas of 31 Mar 2024 | 19.56k | 0.32% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 16.72k | 0.27% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 10.08k | 0.16% |
| Tower Research Capital LLCas of 31 Dec 2023 | 5.92k | 0.10% |
| Timber Point Capital Management LLCas of 31 Dec 2023 | 5.50k | 0.09% |
More ▼
Data from 09 Feb 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
